Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BEN THROWER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1043235211
CMS profile
92186
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$30,380.19

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BEN THROWER

NPI 1043235211 · CMS profile ID 92186

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043235211?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BEN THROWER, NPI 1043235211, CMS profile ID 92186. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043235211?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BEN THROWER, NPI 1043235211, CMS profile ID 92186. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043235211?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BEN THROWER, NPI 1043235211, CMS profile ID 92186, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1043235211?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $30,380.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $14.8307/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040310845 CMS
EMD Serono, Inc. $9.7507/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032319145 CMS
EMD Serono, Inc. $38.4007/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032463177 CMS
EMD Serono, Inc. $12.9507/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032550645 CMS
Celgene Corporation $26.8106/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015979587 CMS
TG Therapeutics, Inc. $24.8806/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503955 CMS
TG Therapeutics, Inc. $8.3806/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503907 CMS
TG Therapeutics, Inc. $22.8406/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503905 CMS
BANNER LIFE SCIENCES, LLC $25.3406/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021111689 CMS
Celgene Corporation $28.3706/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015979567 CMS
GENZYME CORPORATION $21.4205/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049672277 CMS
Horizon Therapeutics plc $200.0005/24/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083423 CMS
Horizon Therapeutics plc $5.0605/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083421 CMS
EMD Serono, Inc. $41.5105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032493119 CMS
EMD Serono, Inc. $32.0505/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032525629 CMS
Celgene Corporation $17.1005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015979521 CMS
Biogen, Inc. $60.0004/27/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012266537 CMS
TG Therapeutics, Inc. $23.6704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503951 CMS
Biogen, Inc. $9.6104/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012262983 CMS
EMD Serono, Inc. $8.2404/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032523859 CMS
Horizon Therapeutics plc $21.7804/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083419 CMS
Biogen, Inc. $15.9904/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012128339 CMS
EMD Serono, Inc. $24.7304/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032426479 CMS
EMD Serono, Inc. $2.0704/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032521139 CMS
EMD Serono, Inc. $22.5104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032493987 CMS
EMD Serono, Inc. $13.2904/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032494009 CMS
Biogen, Inc. $125.0004/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012287873 CMS
Genentech USA, Inc. $21.9303/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040310853 CMS
Novartis Pharmaceuticals Corporation $5.4003/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993351467 CMS
TG Therapeutics, Inc. $24.7303/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503869 CMS
Celgene Corporation $26.6003/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015979501 CMS
Horizon Therapeutics plc $825.0003/15/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083417 CMS
BANNER LIFE SCIENCES, LLC $33.6703/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021109167 CMS
Horizon Therapeutics plc $2,750.0003/09/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083413 CMS
Horizon Therapeutics plc $110.4803/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083415 CMS
Novartis Pharmaceuticals Corporation $23.6603/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993351463 CMS
Biogen, Inc. $22.2103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012242681 CMS
GENZYME CORPORATION $25.8103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049672155 CMS
TG Therapeutics, Inc. $24.4302/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503855 CMS
Novartis Pharmaceuticals Corporation $30.0502/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993351473 CMS
Celgene Corporation $20.8302/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015979481 CMS
Genentech, Inc. $29.0702/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040310865 CMS
TG Therapeutics, Inc. $19.1202/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503859 CMS
Biogen, Inc. $1,503.0002/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012145465 CMS
Novartis Pharmaceuticals Corporation $8.2602/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993351461 CMS
Biogen, Inc. $1,503.0002/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012238891 CMS
AbbVie Inc. $28.2102/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999261087 CMS
Biogen, Inc. $1,503.0002/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012270699 CMS
TG Therapeutics, Inc. $22.1702/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051503891 CMS
Horizon Therapeutics plc $19.6002/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987083411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $19,789.54 64
PY2020 $17,080.97 32
PY2021 $34,624.86 46
PY2022 $38,656.80 112
PY2023 $30,380.19 120
PY2024 $32,142.61 109
PY2025 $29,967.83 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $339,003.67 124
PY2024 Principal investigator $135,378.90 77
PY2023 Principal investigator $278,690.16 94
PY2022 Principal investigator $575,901.19 47
PY2021 Principal investigator $530,824.65 54
PY2020 Recipient $1,575.00 1
PY2020 Principal investigator $791,466.43 42
PY2019 Principal investigator $845,994.23 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $42,425.00 11/30/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198945
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 11/10/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198929
Principal investigator 1 TG Therapeutics, Inc. $17,575.00 11/01/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198943
Principal investigator 1 TG Therapeutics, Inc. $1,402.27 11/01/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198947
Principal investigator 1 TG Therapeutics, Inc. $11,925.00 09/30/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199037
Principal investigator 1 TG Therapeutics, Inc. $761.25 09/30/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199055
Principal investigator 1 TG Therapeutics, Inc. $9,000.00 08/31/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199035
Principal investigator 1 TG Therapeutics, Inc. $38,281.21 08/31/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199053
Principal investigator 1 TG Therapeutics, Inc. $34,048.72 07/31/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199051
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/08/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198923
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 07/02/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226198921
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654150
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654154
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654157
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654160
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654165
Principal investigator 1 Roche Products Limited $173.50 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654169
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654173
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654177
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654181
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654186
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654190
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654194
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654197
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654201
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654205
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654208
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654216
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654219
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654221
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654224
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654228
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654233
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654237
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654241
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654245
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654250
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654254
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654260
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654265
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654269
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654273
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654277
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654280
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654283
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654288
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654293
Principal investigator 1 Roche Products Limited $347.00 06/25/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654297
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 06/23/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199013
Principal investigator 1 Genentech, Inc. $1,816.00 06/13/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653860
Principal investigator 1 Genentech, Inc. $2,472.00 06/13/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653882
Principal investigator 1 Genentech, Inc. $18,659.70 06/06/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653870
Principal investigator 1 Genentech, Inc. $13,982.40 06/06/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653888
Principal investigator 1 TG Therapeutics, Inc. $19,800.00 06/01/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198989
Principal investigator 1 TG Therapeutics, Inc. $9,323.50 06/01/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199019
Principal investigator 1 Genentech, Inc. $8,555.00 04/28/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653865
Principal investigator 1 Genentech, Inc. $2,781.00 04/28/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653873
Principal investigator 1 Genentech, Inc. $13,982.40 04/17/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653893
Principal investigator 1 TG Therapeutics, Inc. $8,500.00 04/15/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199015
Principal investigator 1 TG Therapeutics, Inc. $1,500.00 04/15/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199017
Principal investigator 1 Genentech, Inc. $5,720.00 04/10/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211653878
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 04/02/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab No dispute reported 06/30/2026 1226199011
Principal investigator 1 TG Therapeutics, Inc. $8,300.00 03/31/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198987
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653943
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653967
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654016
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654056
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654081
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654114
Principal investigator 1 Roche Products Limited $347.00 03/24/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654128
Principal investigator 1 TG Therapeutics, Inc. $2,750.00 02/28/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198985
Principal investigator 1 TG Therapeutics, Inc. $3,150.00 02/01/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198983
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653904
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653907
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653912
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653916
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653919
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653925
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653929
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653932
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653937
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653940
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653947
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653949
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653953
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653957
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653963
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653972
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653977
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653982
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653985
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653991
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211653995
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654000
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654005
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654008
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654013
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654019
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654023
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654027
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654032
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654036
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654041
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654046
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654052
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654059
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654063
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654068
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654073
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654076
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654086
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654091
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654095
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654100
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654103
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654108
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654118
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654121
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654124
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654130
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654135
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654140
Principal investigator 1 Roche Products Limited $347.00 01/09/2025 Non-covered Recipient Entity
SHEPHERD CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211654145
Principal investigator 1 TG Therapeutics, Inc. $15,625.00 01/06/2025 Non-covered Recipient Entity
Shepherd Center, Inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226198981